← Back to Patent Explorer
US4636479A Expired / Lapsed US ⏱️ 0.0 years remaining

Enhanced agglutination method and kit

Assignee: LIPSOME TECHNOLOGY Inc
•
Filing: 1983-04-20
•
Granted: 1987-01-13
•
Expires: 2003-04-20
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An enhanced agglutination assay method for determination of a multivalent analyte is disclosed. Analyte is added to agglutinatable particles coated with anti-analyte molecules to produce particle agglutination. The extent of agglutination is enhanced by mixing the particles and analyte with an analyte-binding reagent composed of lipid bodies. The reagent bodies act by promoting multiple analyte bridge connections between individual bridged particles and a reagent body. Also disclosed is a kit containing such particles and reagent.

Inventors

  • 👤 Francis J. Martin
  • 👤 Viola T. Kung

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 22:35
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/576; G01N33/543; G01N33/54393; G01N33/563; G01N33/566; G01N33/567; Y; Y10; Y10S; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/819; Y10S436/829

Claims Analysis

Total Claims: 26
Claim 1
Independent Claim 143 words
An enhanced agglutination assay method for determination of a multivalent analyte in a weakly positive analyte-containing sample, said method comprising: providing an unagglutinated suspension of (a) agglutinatinable particles between about 1 and 20 microns in diameter and having surface-bound anti-analyte molecules effective to produce particle agglutination in the presence of such analyte, and (b) liposomes having surface-bound analyte-binding protein molecules, at an average surface concentration of at least about 15 analyte-binding molecules per liposome, these molecules being effective to bind the analyte concurrently with analyte binding to a particle-bound anti-analyte molecule. adding such analyte-containing sample to the suspension, and by said adding, producing a degree of particle agglutination which is at least 1-2 grades greater, on a 1-4 grade scale, than that which would be produced by adding the anaylte sample to a suspension of the particles in the absence of the liposomes.
Claim 2
Dependent Claim 143 words
An enhanced agglutination assay method for determination of a multivalent analyte in a weakly positive analyte-containing sample, said method comprising: providing an unagglutinated suspension of (a) agglutinatinable particles between about 1 and 20 microns in diameter and having surface-bound anti-analyte molecules effective to produce particle agglutination in the presence of such analyte, and (b) liposomes having surface-bound analyte-binding protein molecules, at an average surface concentration of at least about 15 analyte-binding molecules per liposome, these molecules being effective to bind the analyte concurrently with analyte binding to a particle-bound anti-analyte molecule. adding such analyte-containing sample to the suspension, and by said adding, producing a degree of particle agglutination which is at least 1-2 grades greater, on a 1-4 grade scale, than that which would be produced by adding the anaylte sample to a suspension of the particles in the absence of the liposomes.
Claim 3
Dependent Claim 29 words
The method of claim 1, wherein the liposomes are added such that the resulting reaction medium has a final liposome concentration of between about 10 micromolar and 1 millimolar.
Claim 4
Dependent Claim 22 words
The method of claim 1, wherein the liposomes are composed of lipid-bilayer vesicles in the 0.4 to 10 micron diameter size range.
Claim 5
Dependent Claim 12 words
The method of claim 1, wherein the agglutinatinable particles are latex particles.
Claim 6
Dependent Claim 30 words
The method of claim 1, wherein the analyte molecules include multivalent antigen molecules, and both the particle anti-analyte molecules and the analyte-binding molecules include anti-antigen antibody or antibody fragment molecules.
Claim 7
Dependent Claim 26 words
The method of claim 5, wherein the antigen includes hepatitis B surface antigen, and the antibody or antibody fragment molecules include anti-hepatitis B surface antigen antibodies.
Claim 8
Dependent Claim 19 words
The method of claim 1, wherein the analyte is an IgG, and the analyte-binding molecules, include protein A molecules.
Claim 9
Dependent Claim 27 words
The method of claim 7, wherein the analyte includes anti-nuclear antibody contained in a sample containing non-antigen specific immunoglobulins which are also recognized specifically by protein A.
Claim 10
Dependent Claim 35 words
The method of claim 1, wherein the analyte molecules include antibody molecules which bind immunospecifically to the particle anti-analyte molecules, and the analyte-binding molecules include binding proteins which bind specifically to the analyte antibody molecules.
Claim 11
Dependent Claim 33 words
The method of claim 9, wherein the analyte molecules include IgM molecules and the analyte-binding molecules include anti-IgM antibody or antibody fragment molecules covalently attached to the surface lipid components in the liposomes.
Claim 12
Dependent Claim 12 words
The method of claim 10, wherein the IgM molecules include rheumatoid factor.
Claim 13
Dependent Claim 144 words
An enhanced agglutination assay kit for determination of a multivalent analyte in a weakly positive analyte-containing sample, comprising: an unagglutinated suspension of (a) agglutinatinable particles between about 1 to 20 microns in size, and having surface-bound anti-analyte molecules adapted to promote particle agglutination in the presence of the analyte, and (b) liposomes having surface-bound analyte-binding molecules, at an average concentration of at least about 15 analyte-binding molecules per liposome, these molecules being effective to bind the analyte concurrently with analyte binding to a particle-bound anti-analyte molecule. said liposomes being present in an amount effective to produce a degree of particle agglutination, when such analyte sample is added to the suspension, which is at least 1-2 grades greater, on a 1-4 grade scale, than that which would be produced by adding the analyte to a suspension of the particles in the absence of the liposomes.
Claim 14
Dependent Claim 144 words
An enhanced agglutination assay kit for determination of a multivalent analyte in a weakly positive analyte-containing sample, comprising: an unagglutinated suspension of (a) agglutinatinable particles between about 1 to 20 microns in size, and having surface-bound anti-analyte molecules adapted to promote particle agglutination in the presence of the analyte, and (b) liposomes having surface-bound analyte-binding molecules, at an average concentration of at least about 15 analyte-binding molecules per liposome, these molecules being effective to bind the analyte concurrently with analyte binding to a particle-bound anti-analyte molecule. said liposomes being present in an amount effective to produce a degree of particle agglutination, when such analyte sample is added to the suspension, which is at least 1-2 grades greater, on a 1-4 grade scale, than that which would be produced by adding the analyte to a suspension of the particles in the absence of the liposomes.
Claim 15
Dependent Claim 23 words
The kit of claim 12, wherein the concentration of liposomes supplied is between about 20 micromolar and 1 millimolar in the reaction medium.
Claim 16
Dependent Claim 22 words
The kit of claim 12, wherein the liposomes are composed of lipid-bilayer vesicles in the 0.4 to 10 micron diameter size range.
Claim 17
Dependent Claim 26 words
The kit of claim 12, wherein the particles include polymeric beads, and the liposomes include more than about 20 mole percent of negatively charged lipid components.
Claim 18
Dependent Claim 27 words
The kit of claim 12 wherein the particles include red blood cells, and the liposomes include less than about 20 moles percent of negatively charged lipid components.
Claim 19
Dependent Claim 12 words
The kit of claim 12, wherein the agglutinatinable particles are latex particles.
Claim 20
Dependent Claim 20 words
The kit of claim 12, wherein the suspension further includes ribbon-like lipid bilayer structures formed by freezing and thawing liposomes.
Claim 21
Dependent Claim 36 words
The kit of claim 12 for use in determination of an antibody analyte, wherein the particle anti-analyte molecules and the analyte-binding molecules include binding proteins adapted to bind specifically to the molecules of the analyte antibody.
Claim 22
Dependent Claim 45 words
The kit of claim 19 for use in determination of an IgM analyte such as rheumatoid factor, wherein the particle anti-analyte molecules include IgG molecules, and the analyte-binding molecules include anti-IgM antibody or antibody fragment molecules covalently attached to surface lipid components in the liposomes.
Claim 23
Dependent Claim 29 words
The kit of claim 12, for use in determination of a multivalent antigen, wherein both the particle anti-analyte molecules and analyte-binding molecules include anti-antigen antibody or antibody fragment molecules.
Claim 24
Dependent Claim 27 words
The kit of claim 11 for use in determination of hepatitis B surface antigen, wherein the antibody or antibody fragment molecules include anti-hepatitis B surface antigen antibodies.
Claim 25
Dependent Claim 52 words
The kit of claim 12, for use in determining an antigen-specific immunoglobulin which is recognized specifically by protein A and which is contained in a sample containing non-antigen-specific immunoglobulins which are recognized specifically by protein A, wherein the particles have surface-bound antigen molecules and the reagent analyte-binding molecules include protein A molecules.
Claim 26
Dependent Claim 11 words
The kit of claim 23, wherein the antigen includes anti-nuclear antibody.

References Cited (Backward Citations)

US4216622A Cited
WO1983001571A1 Cited
US4429008A Cited
US4429008B1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-01-12 1990-07-14 1991-01-13 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-01-12 1994-07-14 1995-01-13 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-01-12 1998-07-14 1999-01-13 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag